Centre Hospitalier Lyon Sud

At Centre Hospitalier Lyon Sud, a major share of research focuses on neoplasms and blood cancers, with studies spanning lymphoma, multiple myeloma, leukemia, and solid tumors. These trials are largely designed to test new treatments, compare treatment strategies, and improve outcomes for patients with relapsed, refractory, or high-risk disease.

• Research in diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and other non-Hodgkin lymphomas
• Studies in acute myeloid leukemia, myelodysplastic syndrome, and related myeloproliferative disorders
• Trials in multiple myeloma and plasma cell disorders assessing new combinations and maintenance approaches

Much of this work aims to refine cancer control, extend remission, and identify more effective options for patients who have already received standard care.

The site also supports a strong program in breast cancer, prostate cancer, and urothelial cancer. These studies explore whether newer therapies, radiation-based strategies, and combined treatment plans can improve survival and reduce the chance of recurrence in both early and advanced disease.

• Breast cancer research in hormone receptor-positive, HER2-positive, and metastatic settings
• Prostate cancer trials focused on localized, metastatic, and castration-resistant disease
• Bladder and urothelial cancer studies evaluating better options after surgery or chemoradiotherapy

These trials often compare established care with newer targeted or immunotherapy-based approaches to see which can better delay disease progression.

Another important research area at this hospital is the study of advanced solid tumors, especially melanoma and non-small cell lung cancer. The goal is to evaluate new immunotherapies and targeted treatments, particularly for patients with metastatic or treatment-resistant disease.

• Melanoma studies in advanced, unresectable, and brain-metastatic disease
• Non-small cell lung cancer trials in locally advanced and metastatic settings
• Broader pan-tumor research examining treatment benefit across multiple cancer types

Work in this area is aimed at improving tumor response, extending survival, and broadening treatment options for people with difficult-to-treat cancers.

Clinical research here is not limited to cancer. The site also studies immune system diseases and digestive system diseases, including ulcerative colitis, Crohn's disease, atopic dermatitis, and chronic urticaria. These trials focus on better disease control, symptom relief, and long-term safety of newer therapies.

• Inflammatory bowel disease research in ulcerative colitis and Crohn's disease
• Dermatology studies in atopic dermatitis and urticaria
• Investigations of treatment monitoring and care strategies for chronic inflammatory conditions

These studies are designed to improve everyday disease management and help patients maintain better quality of life over time.

Reflecting the department’s Radiotherapy focus, the site participates in trials that combine radiation therapy with systemic treatments for cancers such as cervical cancer, head and neck cancer, prostate cancer, and bladder cancer. These studies aim to improve local control, prevent spread, and strengthen overall treatment effectiveness.

• Locally advanced cervical cancer and other pelvic malignancies
• Head and neck cancer and skin cancer research involving surgery and radiation
• Prostate cancer trials combining radiotherapy with hormone-based treatment

By integrating radiation with modern oncology care, the site is helping evaluate whether combined approaches can deliver better outcomes than standard treatment alone.

Beyond major cancer programs, Centre Hospitalier Lyon Sud is involved in studies of hematologic diseases, rare blood disorders, and selected chronic conditions such as amyloidosis, myelofibrosis, polycythemia vera, and paroxysmal nocturnal hemoglobinuria. Some trials also address non-oncology problems, including cystic fibrosis, cardiovascular disease, and metabolic or liver disorders.

• Myeloproliferative neoplasms and other blood disorders
• Amyloidosis and other rare systemic diseases
• Cystic fibrosis and additional chronic non-cancer conditions

These studies broaden the research portfolio by exploring new ways to improve disease control, safety, and long-term patient care across several specialty areas.